• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PharmaNet Stock Plunges 60% After Cancellations

PharmaNet Stock Plunges 60% After Cancellations

September 12, 2008
CenterWatch Staff

PharmaNet Development Group’s shares plunged more than 60% to less than $10 a share in early morning trading after the contract research organization (CRO) cut its financial guidance for the year. The company expects a loss—instead of the previously predicted profit—following cancellations and postponements of projects by biotech and pharmaceutical companies.

"After the strong new business wins in the second quarter 2008, we are very disappointed with the level of late stage project cancellations and a significant project postponement that occurred in the third quarter," said Jeffrey P. McMullen, PharmaNet’s president and CEO. "We were able to recover in the second quarter 2008 from earlier cancellations and we are confident that our determined business development efforts and existing backlog will drive us to profitability in 2009.”

By late morning Friday, PharmaNet’s shares had recovered a bit, but were still down 55% at $10.43.

For its full year, the company now expects a loss of 25 cents to 58 cents a share, compared with its earlier estimate of earnings of 53 cents to 63 cents a share.

PharmaNet’s revenue is expected to be in a range of $358 million to $368 million, cut from a previous forecast of $390 million to $399 million.

The company’s cancellation rate for late-stage projects jumped to 32.7%, from 8.4% in July.

In its previous quarter, PharmaNet had made a comeback, swinging to a second-quarter profit and easily beating analysts' expectations. At the time, the company saw continued strong growth for the rest of the year as well as for 2009.

The company said the cancellations included $19 million of expected late stage direct revenue in the second half of 2008 from two contracts and a reduction of $6 million of expected early stage direct revenue from a postponement.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing